A Depression Drug Maker With a Phase 3 Readout Weeks Away

Sponsored by

Finally, a Monday that doesn’t feel like one.

Imagine a Saturday where you're not catching up on the CRM you didn't touch all week. 

HubSpot's new self-updating CRM doesn't wait for you to log back in. Friday's calls are already logged. The deal that needs a nudge Monday morning is already flagged. The automation you set up once keeps running without you thinking about it. None of it needed you over the weekend. 

Customers are already seeing it pay off: 45% more deals closed. Finally, you start Monday caught up, not behind.

Get a Demo

30‑Second Take

Axsome already sells three CNS drugs: Auvelity for depression (and, since April, for agitation in Alzheimer's dementia), Sunosi for excessive daytime sleepiness, and Symbravo for migraine.

The near-term swing factor is the ENGAGE Phase 3 trial of Sunosi (solriamfetol) in binge eating disorder, with topline results guided for the fourth quarter of 2026. That means it could land any week now.

Behind it sits a May 1, 2027 PDUFA date for AXS-12 in cataplexy in narcolepsy.

The stock has slid hard from its 52-week high as the Alzheimer's agitation launch ramped slower than the Street hoped. You're buying a CNS growth story at a reset price, right before the catalysts hit.

Trade Setup

Timeframe: 4 to 12 weeks
Edge type: Binary catalyst into oversold setup

The thesis is a classic pre-readout setup. AXSM fell for 12 straight sessions into mid-October as RBC and Deutsche Bank trimmed price targets, so expectations are reset. ENGAGE is a true binary event.

A positive result gives Sunosi a second major indication in a market with essentially one approved drug. A failure gets ugly fast. Size this like a biotech catalyst trade, not a core holding. You want exposure, not a bet-the-house position.

Leave Granola and get up to 12 months free of Wispr Flow Notetaker + Dictation

If you have paid time left on an individual Granola plan, we'll match it with a Wispr Flow subscription that includes Notetaker and dictation, and add bonus time, up to 12 months total. Sign in or create a Wispr account and submit proof of your plan to check eligibility.

Try Notetaker Free

Snapshot Table

Chart

1-Month Trading Summary

AXSM lost about 22% over the past month, sliding from around $205 in late September into the high $150s. That included 12 straight down sessions into mid-October and a 6% drop on October 13 as price-target cuts piled up.

It has steadied in the mid-to-high $150s since, with volume cooling off from the selloff days. The good news if you're a buyer: expectations are reset, and the ENGAGE readout window is now open.

Bull Case 

Why It Works

The real asset here is the pipeline layered on a growing commercial base. Product revenue rose 46% year over year in the second quarter to roughly $218 million, led by Auvelity.

ENGAGE tests Sunosi, a drug Axsome already sells, in a brand-new indication. You're paying for the commercial business and getting a second shot on goal for free.

The Catalysts

ENGAGE is the near-term swing factor. The trial tests two doses of Sunosi (solriamfetol) against placebo over 12 weeks in adults with binge eating disorder, a condition with essentially one FDA-approved drug today.

Positive data would hand Axsome a second major indication for a drug it already sells, meaning no new sales force needed. You just expand the label.

The cataplexy in narcolepsy opportunity gets less airtime, but it matters. The FDA accepted the AXS-12 NDA in July, set a PDUFA target action date of May 1, 2027, and said it does not currently plan an advisory committee.

That's your second shot on goal in the next seven months. If Axsome lands both a positive ENGAGE readout and AXS-12 approval, you're looking at a very different company by mid-2027.

What The Numbers Say

At roughly an $8.4B market cap, you're not paying mega-cap biotech premiums for a company with growing product revenue and two late-stage catalysts inside seven months.

The stock sits nearly 40% below its 52-week high, while Wall Street targets still sit far above it (Needham reiterated Buy with a $268 target on October 15). The setup rewards you for being early.

Bear Case 

What Could Break It

Biotech binary trades cut both ways. If ENGAGE misses on efficacy or throws up a safety signal, this stock loses 30% to 40% in a day. That's the honest downside you need to accept before putting money to work.

The commercial Auvelity story has issues too. Scripts have been growing, but the Alzheimer's agitation ramp has been slower than bulls modeled, which is a big part of why the stock gave back so much from the highs.

Payer pushback and prior authorization headaches are real for CNS launches. If management can't accelerate the trajectory, your "one Phase 3 readout away" thesis gets harder to sustain.

The Valuation Risk

Competition is another overhang. The depression market is crowded, and binge eating disorder has at least one established player with brand loyalty.

Even positive data doesn't guarantee commercial success. You still need a differentiated label and reimbursement, and the current $8.36B cap already bakes in meaningful optionality.

How To Size It

Axsome burns cash building the commercial organization and running trials. If any of the near-term catalysts disappoint, raising money gets more expensive and more dilutive.

Keep an eye on the next quarterly cash balance. Size this like a catalyst trade, not a core position. A failed readout can erase a year of patience in a single session.

Quick Checklist 

✅ Thesis still valid after the latest close
✅ Volume confirms setup above $155 support
✅ Catalyst date confirmed: ENGAGE Phase 3 topline guided for Q4 2026

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha